Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 19:15:1297542.
doi: 10.3389/fimmu.2024.1297542. eCollection 2024.

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

Yi Huang  1   2 , Chengxiao Liao  1   2 , Zefeng Shen  3 , Yitong Zou  1   2 , Weibin Xie  1   2 , Qinghua Gan  1   2 , Yuhui Yao  1   2 , JunJiong Zheng  1   2 , Jianqiu Kong  1   2
Affiliations

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

Yi Huang et al. Front Immunol. .

Abstract

Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the cornerstone of treatment for muscle-invasive bladder cancer (MIBC). While platinum-based regimens have demonstrated benefits in tumor downstaging and improved long-term survival for selected patients, they may pose risks for those who are ineligible or unresponsive to chemotherapy.

Objective: We undertook a bibliometric analysis to elucidate the breadth of literature on NAC in bladder cancer, discern research trajectories, and underscore emerging avenues of investigation.

Methods: A systematic search of the Web of Science Core Collection (WoSCC) was conducted to identify articles pertaining to NAC in bladder cancer from 1999 to 2022. Advanced bibliometric tools, such as VOSviewer, CiteSpace, and SCImago Graphica, facilitated the examination and depicted the publication trends, geographic contributions, institutional affiliations, journal prominence, author collaborations, and salient keywords, emphasizing the top 25 citation bursts.

Results: Our analysis included 1836 publications spanning 1999 to 2022, indicating a growing trend in both annual publications and citations related to NAC in bladder cancer. The United States emerged as the predominant contributor in terms of publications, citations, and international collaborations. The University of Texas was the leading institution in publication output. "Urologic Oncology Seminars and Original Investigations" was the primary publishing journal, while "European Urology" boasted the highest impact factor. Shariat, Shahrokh F., and Grossman, H.B., were identified as the most prolific and co-cited authors, respectively. Keyword analysis revealed both frequency of occurrence and citation bursts, highlighting areas of concentrated study. Notably, the integration of immunochemotherapy is projected to experience substantial growth in forthcoming research.

Conclusions: Our bibliometric assessment provides a panoramic view of the research milieu surrounding neoadjuvant chemotherapy for bladder cancer, encapsulating the present state, evolving trends, and potential future directions, with a particular emphasis on the promise of immunochemotherapy.

Keywords: bibliometrics; bladder cancer; immune checkpoint inhibitors; neoadjuvant chemotherapy; platin-based.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer XD declared a shared parent affiliation with the authors YH, CL, YZ, WX, QG, YY, JZ and JK to the handling editor at the time of review.

Figures

Figure 1
Figure 1
Annual trends of global publications and citations. (A) Numbers of publications and citations on NAC for bladder cancer from 1999 to 2021. (B) Polynomial fitting curve of annual publication in NAC for bladder cancer.
Figure 2
Figure 2
Analysis of global research trends and collaborations. (A) The total link strength of publications in different countries/regions. (B) The composition of annual publications in terms of the top 10 productive countries/regions. (C) Visualization graph of collaborations between countries/regions in NAC for bladder cancer. the sizes of the bubbles bearing the names of countries correspond to the respective quantities of publications, while the color of the bubbles represents the total link strength (TLS). Connection lines between countries denote cooperation relationships.
Figure 3
Figure 3
Visualization graph of collaborations between institutes in NAC for bladder cancer with a minimum of 5 documents. Each node represents an institute, with node size indicating their publication volume, and the lines between institutions representing their collaborations.
Figure 4
Figure 4
Visualization graph of collaborations between journals in NAC for bladder cancer with a minimum of 5 documents. Each node represents a journal, with node size indicating their publication volume, and the lines between journals representing their collaborations (A). (B) The dual-map overlay of journals related to NAC for bladder cancer. The citing journals were on the left, the cited journals were on the right, and the colored path represents the citation relationship.
Figure 5
Figure 5
Analysis of authors and co-cited authors with a minimum of 5 citations. (A) The visualization map of authors analysis. (B) The visualization map of co-cited authors analysis. Each node represents an author or co-cited author, with node size indicating their citations or documents, and the lines between authors representing their collaborations.
Figure 6
Figure 6
Visualization graph of co-cited references analysis with a minimum of 20 citations. the size of each bubble and the quantity of connected lines represent the TLS and correlations among co-cited references, respectively.
Figure 7
Figure 7
Visualization graph of keywords co-occurrence analysis with a minimum of 5 occurrence each node represents a keyword, with node size indicating their occurrence times, and the lines between keywords representing their collaborations (A). (B) Top 25 keywords with the strongest citation bursts.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol (2023) 20:287–304. doi: 10.1038/s41571-023-00744-3 - DOI - PubMed
    1. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. . Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol (2003) 21:690–6. doi: 10.1200/jco.2003.05.101 - DOI - PubMed
    1. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol (2006) 176:486–92; discussion 491-2. doi: 10.1016/j.juro.2006.03.038 - DOI - PubMed
    1. Raghavan D. Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer. Br J Urol (1988) 61:1–8. doi: 10.1111/j.1464-410x.1988.tb09152.x - DOI - PubMed

Publication types